FindMyKOL

Sheila Lezcano, MD

Basic profile

Cedars-Sinai Medical Center

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionLos Angeles, CA · WestSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLFindMyKOL type: RegionalLatest publication2011Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Sheila Lezcano is a Rheumatology/Immunology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 15 publications with 723 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
15publications

Publications indexed by OpenAlex. Counts exclude supporting files.

723citations

Citations across these publications.

8h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
10companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • ABBVIE INC.
    Program year202513 payments
    $144
  • GlaxoSmithKline, LLC.
    Program year20251 payment
    $32
  • ABBVIE INC.
    Program year202412 payments
    $181
All 17 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    37.6%
    Folate Analog Metabolic Inhibitor11.1%
    Methotrexate91%Rasuvo9%
    Part D<11 patients
    TNF inhibitor10.9%
    Humira Pen34%Enbrel Sureclick23%Enbrel17%Simponi13%Enbrel Mini7%Humira(Cf)6%
    Part D<11 patients

    + 6 more classes in this area

  • Nervous system

    17.2%
    Gabapentinoids8%
    Gabapentin60%Pregabalin40%
    Part D≥30 patients
    Nonsteroidal Anti-inflammatory Drug5.2%
    Ibuprofen83%Meloxicam17%
    Part D<11 patients

    + 3 more classes in this area

  • Musculoskeletal

    13.4%
    Nonsteroidal Anti-inflammatory Drug10%
    Diclofenac Sodium80%Naproxen13%Sulindac7%
    Part D<11 patients
    RANK Ligand Inhibitor1.1%
    Prolia100%
    Part D≥18 patients

    + 3 more classes in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”